Free Trial
NYSE:MRK

Merck & Co., Inc. Q2 2025 Earnings Report

Merck & Co., Inc. logo
$80.74 +1.58 (+1.99%)
As of 10:40 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Merck & Co., Inc. EPS Results

Actual EPS
N/A
Consensus EPS
$2.03
Beat/Miss
N/A
One Year Ago EPS
N/A

Merck & Co., Inc. Revenue Results

Actual Revenue
N/A
Expected Revenue
$15.92 billion
Beat/Miss
N/A
YoY Revenue Growth
N/A

Merck & Co., Inc. Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Tuesday, July 29, 2025
Conference Call Time
9:00AM ET

Conference Call Resources

Merck & Co., Inc. Earnings Headlines

A grave, grave error.
President Donald Trump made headlines last month with a staggering claim. He stated that since taking office, more than $12 trillion in private investments into America have been “practically committed” on his watch. "Nobody's ever seen numbers like we have," he said, crediting his agenda of tariffs, tax cuts, and deregulation with making the difference. If true, the figure would indeed be astonishing – potentially tripling the roughly $4 trillion in gross private investment the US reported all of last year.
Merck: Don't Let Today's Bargain Opportunity Pass You By
MRK - Merck & Co Inc Dividends - Morningstar
MRK - Merck & Co Inc Price vs Fair Value - Morningstar
See More Merck & Co., Inc. Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Merck & Co., Inc.? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Merck & Co., Inc. and other key companies, straight to your email.

About Merck & Co., Inc.

Merck & Co., Inc. (NYSE:MRK) (NYSE: MRK) is a global research-driven pharmaceutical company headquartered in Kenilworth, New Jersey. Founded in 1891 as an American extension of the German Merck family’s business, it has grown into one of the largest and most respected names in healthcare. From its early work on insulin production to its leadership in vaccine development, Merck has maintained a strong commitment to scientific innovation and public health.

The company’s principal business activities span the discovery, development, manufacturing and marketing of prescription medicines, vaccines and animal health products. Merck’s human health portfolio includes therapies in oncology, immunology, infectious diseases, cardiometabolic disorders and neuroscience. Key products include leading cancer immunotherapies and vaccines designed to prevent diseases such as HPV, shingles and pneumonia. Its Animal Health division offers vaccines, pharmaceuticals and services aimed at improving the health and productivity of livestock and companion animals.

Research and development play a central role in Merck’s strategy. The company operates research facilities in North America, Europe and Asia, and engages in collaborations with academic institutions, biotech firms and health organizations worldwide. Over its history, Merck has introduced numerous breakthrough therapies, including the first mumps vaccine in the 1960s and pioneering antiviral treatments. Its robust pipeline addresses both established and emerging health challenges, reflecting a sustained investment in early-stage research through late-stage clinical development.

Merck serves customers in more than 140 countries, supported by a network of manufacturing sites and distribution partners. Its leadership team is led by President and CEO Robert M. Davis, who brings decades of experience in the pharmaceutical industry. The board of directors provides governance and oversight under the chairmanship of Kenneth C. Frazier, a former CEO who guided the company through significant growth and diversification. Together, Merck’s leadership fosters a culture of integrity, patient focus and shared value for stakeholders worldwide.

View Merck & Co., Inc. Profile

More Earnings Resources from MarketBeat